| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||
| Coenzyme Q10 (CoQ10), also known as ubiquinone, is a fat-soluble antioxidant and a critical component of the mitochondrial electron transport chain, essential for ATP production. Its potential role in Alzheimer’s disease (AD) and cancer has been increasingly studied, mainly due to its effects on oxidative stress, mitochondrial function, and cellular energy metabolism. Two types: ubiquinone(standard) vs ubiquinol(more bioavailable) -high content in beef heart -Acts as an antioxidant, reducing ROS -Some preclinical studies suggest CoQ10 may reduce Aβ-induced neurotoxicity -CoQ10 is sometimes used with chemotherapy to reduce cardiotoxicity (especially with doxorubicin). -Essential for ATP (energy) production. -CoQ10 levels may drop by 25–40% in people taking statins. -May support mitochondrial function in neurodegenerative diseases, including Alzheimer’s and Parkinson’s Coenzyme Q10 exists in three redox states: Form Name Abbreviation Redox state Oxidized Ubiquinone CoQ10 Oxidized (labeled “Coenzyme Q10”, “CoQ10”) Semiquinone Ubiquinol radical CoQ10•– Intermediate (labeled “Ubiquinol”, “Reduced CoQ10”) Reduced Ubiquinol CoQ10H₂ Reduced Most supplements = ubiquinol (reduced, antioxidant) Ubiquinol is often preferred for cardiovascular, aging, and antioxidant-focused use. BPM31510 = ubiquinone (oxidized) (might raise ROS in cancer cells) >80–95% of circulating CoQ10 is ubiquinol, regardless of whether ubiquinone or ubiquinol was ingested -CoQ10 is fat-soluble, so take it alongside meals that include nutrient-dense fats like coconut oil, butter or tallow in moderation -initial 200-300mg/day (split during day) down to 100mg after 21 days BPM31510: Pharmaceutical oxidized CoQ10 BPM31510 = oxidized CoQ10 (ubiquinone) in a specialized lipid formulation. BPM31510 increases Mitochondrial ROS in cancer cells. That increase is intentional, central to its mechanism, and relatively selective for tumor cells. BPM31510 Studies report in cancer cells: ↑ mitochondrial ROS ↑ lipid peroxidation ↓ NADPH/NADP⁺ ratio ↓ GSH/GSSG ratio Activation of oxidative stress pathways Cell death without classic antioxidant rescue Importantly: Trolox, NAC, or GSH can partially blunt BPM31510 effects, confirming ROS dependence Coenzyme Q10 (CoQ10 / Ubiquinone) — Cancer vs Normal Cell Effects
|
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| - | in-vitro, | CRC, | NA |
| 4772- | CoQ10, | The anti-tumor activities of coenzyme Q0 through ROS-mediated autophagic cell death in human triple-negative breast cells |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MDA-MB-231 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:356 Target#:42 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid